Ypsomed announced today that, at its annual general meeting, its shareholders approved all proposals, including facility expansions.
Burgdorf, Switzerland-based Ypsomed develops drug delivery devices, including insulin pumps for those with diabetes. Its YpsoPump represents a leading offering as an automated insulin delivery system compatible with certain software and glucose monitors.
Board member Simon Michel confirmed the company’s commitment to Switzerland as a manufacturing location at the annual meeting. Ypsomed expects to create 200 new jobs in Burgdorf and Solothurn in the current financial year, on top of expansions elsewhere.
Get the full story at our sister site, Drug Delivery Business News.
